Clinical trial
Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer…
NCT00133900 · Immunicon, Industry · Unknown status
Key facts
| NCT number | NCT00133900 |
|---|---|
| Title | Circulating Tumor Cells and Survival in Hormone Refractory Prostate Cancer (HRPC) Patients Receiving Chemotherapy |
| Official title | Circulating Tumor Cells and the Prediction of Overall Survival in Patients With Androgen Independent Prostate Cancer Entering Onto Chemotherapy |
| Acronym | IMMC-38 |
| Lead sponsor | Immunicon, Industry |
| Status | Unknown status |
| Study type | Observational |
| Conditions | Hormone Refractory Prostate Cancer, Prostate Cancer |
| Intervention type | Procedure |
| Interventions | Phlebotomy |
| Enrollment | 276 |
| Start date | Dec 1, 2004 |
| Primary completion | Feb 1, 2009 |
| Completion | Feb 1, 2009 |
| First posted | Aug 24, 2005 |
| Last update posted | Jul 28, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: